VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2021 | αβ T-cell depleted allo-HSCT for hematological malignancies

Jürgen Kuball, MD, PhD, Utrecht University, Utrecht University, Netherlands, summarizes the findings of a Phase I/II study (#NL4767) investigating αβ T-cell depleted allogeneic hematopoietic stem cell transplantation (allo-HSCT) for hematological malignancies. The study, which enrolled 35 patients, reported that only 26% of patients developed acute graft-versus-host-disease (GvHD) grade 2-4 within 100 days of allo-HSCT, and that αβ T-cell depleted allo-HSCT was associated with a low incidence of chronic GvHD after two years. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Transcript (edited for clarity)

We just published in Blood Advances a very exciting paper on a new transplantation platform where we deplete ex-vivo alpha/beta T-cells from graft, and then infuse them into patients with related and unrelated donors. The findings are really quite exciting, because we see that on the one hand we really reduce acute toxicity in the very beginning, and on the other hand, in the long run, we hardly see one of the major challenges for surviving patients, chronic GVHD...

We just published in Blood Advances a very exciting paper on a new transplantation platform where we deplete ex-vivo alpha/beta T-cells from graft, and then infuse them into patients with related and unrelated donors. The findings are really quite exciting, because we see that on the one hand we really reduce acute toxicity in the very beginning, and on the other hand, in the long run, we hardly see one of the major challenges for surviving patients, chronic GVHD.

[Inaudible] chronic GVHD is literally something all our new fellows won’t even know, because it’s nearly absent. I think this is really a game changer, a game changer because on the one hand, this platform will allow very early immune interventions in the future. So, for example, adding DLIs, but also next generation of CAR-Ts. On the other hand, it impacts the quality of life in a positive way, so that patients in the long run might be earlier able to go back to normal life and do their daily business, enjoy life.

Read more...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter